The JI PBL Intereron Source
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chan, G. C.
Right arrow Articles by Marsden, P. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chan, G. C.
Right arrow Articles by Marsden, P. A.
The Journal of Immunology, 2005, 175: 3846-3861.
Copyright © 2005 by The American Association of Immunologists

Epigenetic Basis for the Transcriptional Hyporesponsiveness of the Human Inducible Nitric Oxide Synthase Gene in Vascular Endothelial Cells1

Gary C. Chan*, Jason E. Fish{dagger}, Imtiaz A. Mawji*, Desmond D. Leung{ddagger}, Alisa C. Rachlis{ddagger} and Philip A. Marsden2,*,{dagger},{ddagger}

* Department of Laboratory Medicine and Pathobiology and {dagger} Department of Medical Biophysics, University of Toronto, Toronto, Canada; and {ddagger} Renal Division and Department of Medicine, St. Michael’s Hospital and University of Toronto, Toronto, Canada

A marked difference exists in the inducibility of inducible NO synthase (iNOS) between humans and rodents. Although important cis and trans factors in the murine and human iNOS promoters have been characterized using episomal-based approaches, a compelling molecular explanation for why human iNOS is resistant to induction has not been reported. In this study we present evidence that the hyporesponsiveness of the human iNOS promoter is based in part on epigenetic silencing, specifically hypermethylation of CpG dinucleotides and histone H3 lysine 9 methylation. Using bisulfite sequencing, we demonstrated that the iNOS promoter was heavily methylated at CpG dinucleotides in a variety of primary human endothelial cells and vascular smooth muscle cells, all of which are notoriously resistant to iNOS induction. In contrast, in human cell types capable of iNOS induction (e.g., A549 pulmonary adenocarcinoma, DLD-1 colon adenocarcinoma, and primary hepatocytes), the iNOS promoter was relatively hypomethylated. Treatment of human cells, such as DLD-1, with a DNA methyltransferase inhibitor (5-azacytidine) induced global and iNOS promoter DNA hypomethylation. Importantly, 5-azacytidine enhanced the cytokine inducibility of iNOS. Using chromatin immunoprecipitation, we found that the human iNOS promoter was basally enriched with di- and trimethylation of H3 lysine 9 in endothelial cells, and this did not change with cytokine addition. This contrasted with the absence of lysine 9 methylation in inducible cell types. Importantly, chromatin immunoprecipitation demonstrated the selective presence of the methyl-CpG-binding transcriptional repressor MeCP2 at the iNOS promoter in endothelial cells. Collectively, our work defines a role for chromatin-based mechanisms in the control of human iNOS gene expression.




This article has been cited by other articles:


Home page
Circ. Res.Home page
C. C. Matouk and P. A. Marsden
Epigenetic Regulation of Vascular Endothelial Gene Expression
Circ. Res., April 25, 2008; 102(8): 873 - 887.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
Y. Zhang, V. Brovkovych, S. Brovkovych, F. Tan, B.-S. Lee, T. Sharma, and R. A. Skidgel
Dynamic Receptor-dependent Activation of Inducible Nitric-oxide Synthase by ERK-mediated Phosphorylation of Ser745
J. Biol. Chem., November 2, 2007; 282(44): 32453 - 32461.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D. M.E.I. Hellebrekers, V. Melotte, E. Vire, E. Langenkamp, G. Molema, F. Fuks, J. G. Herman, W. Van Criekinge, A. W. Griffioen, and M. van Engeland
Identification of Epigenetically Silenced Genes in Tumor Endothelial Cells
Cancer Res., May 1, 2007; 67(9): 4138 - 4148.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
Z. Guo, L. Shao, Q. Du, K. S. Park, and D. A. Geller
Identification of a classic cytokine-induced enhancer upstream in the human iNOS promoter
FASEB J, February 1, 2007; 21(2): 535 - 542.
[Abstract] [Full Text] [PDF]


Home page
Mol. Pharmacol.Home page
C.-H. Leung, S. P. Grill, W. Lam, W. Gao, H.-D. Sun, and Y.-C. Cheng
Eriocalyxin B Inhibits Nuclear Factor-{kappa}B Activation by Interfering with the Binding of Both p65 and p50 to the Response Element in a Noncompetitive Manner
Mol. Pharmacol., December 1, 2006; 70(6): 1946 - 1955.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
M. Liu, M. Mendicino, Q. Ning, A. Ghanekar, W. He, I. McGilvray, I. Shalev, D. Pivato, D. A. Clark, M. J. Phillips, et al.
Cytokine-Induced Hepatic Apoptosis Is Dependent on FGL2/Fibroleukin: The Role of Sp1/Sp3 and STAT1/PU.1 Composite cis Elements.
J. Immunol., June 1, 2006; 176(11): 7028 - 7038.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2005 by The American Association of Immunologists, Inc. All rights reserved.